Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
IsraelIPO:
15 May 1998Website:
http://www.protalix.comNext earnings report:
14 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 19 Nov 2024 23:01:50 GMTDividend
Analysts recommendations
Institutional Ownership
PLX Latest News
Protalix BioTherapeutics, Inc. (NYSE:PLX ) Q3 2024 Results Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Mike Moyer - Investor Relations, LifeSci Advisors Dror Bashan - President and Chief Executive Officer Eyal Rubin - Senior Vice President and Chief Financial Officer Conference Call Participants John Vandermosten - Zacks Investment Research Daniel Smith - H.C. Wainwright & Co., LLC Robert Sassoon - Water Tower Research Operator Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics Third Quarter 2024 Financial and Business Results Conference Call.
The Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com The Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel , Aug. 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended June 30, 2024, and provided a business update.
PHILADELPHIA, PA / ACCESSWIRE / June 11, 2024 / Kaskela Law LLC announces that it is investigating Protalix BioTherapeutics, Inc. (NYSE:PLX) ("Protalix") on behalf of the company's shareholders. Since May 2023, shares of Protalix common stock have declined in value from a trading price of approximately $3.25 per share to a current trading price of below $1.25 per share, a decline of over 61% in value.
Protalix BioTherapeutics, Inc. (PLX) Q4 2023 Earnings Call Transcript
Corporate presentation scheduled for Monday, February 26, 2024 at 1:00 PM ET CARMIEL, Israel , Feb. 23, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced that it will attend and present at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 at the New York Marriott Marquis in New York City. Management is scheduled to give a corporate overview at the BIO CEO & Investor Conference on Monday, February 26, 2024 at 1:00 PM ET at the Plymouth Room and will be available to participate in one-on-one partnering meetings with registered investors and other conference attendees.
Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , July 31, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the second quarter ended June 30, 2023 and provide a business update on Monday, August 7, 2023.
Protalix received FDA and EU approval for Elfabrio. This puts the company on track for profitability as early as 2023. With a reasonable valuation and strong growth, I see a significant potential upside for PLX stock.
What type of business is Protalix BioTherapeutics?
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
What sector is Protalix BioTherapeutics in?
Protalix BioTherapeutics is in the Healthcare sector
What industry is Protalix BioTherapeutics in?
Protalix BioTherapeutics is in the Biotechnology industry
What country is Protalix BioTherapeutics from?
Protalix BioTherapeutics is headquartered in Israel
When did Protalix BioTherapeutics go public?
Protalix BioTherapeutics initial public offering (IPO) was on 15 May 1998
What is Protalix BioTherapeutics website?
https://www.protalix.com
Is Protalix BioTherapeutics in the S&P 500?
No, Protalix BioTherapeutics is not included in the S&P 500 index
Is Protalix BioTherapeutics in the NASDAQ 100?
No, Protalix BioTherapeutics is not included in the NASDAQ 100 index
Is Protalix BioTherapeutics in the Dow Jones?
No, Protalix BioTherapeutics is not included in the Dow Jones index
When was Protalix BioTherapeutics the previous earnings report?
No data
When does Protalix BioTherapeutics earnings report?
The next expected earnings date for Protalix BioTherapeutics is 14 March 2025